Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent to treat eosinophilic esophagitis, or EoE, in children as young as one year of age. Specifically, the approval covers children aged one to 11 years who weigh at least 15 kg and who are inadequately controlled by, intolerant to, or who are not candidates for conventional medicinal therapy. This expands the initial approval in the European Union, or EU, for EoE in adults and adolescents and makes Dupixent the first and only medicine indicated to treat these young patients. Dupixent is also approved in this young age group in the U.S. and Canada.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $1,126 from $1,137 at Truist
- Regeneron price target lowered to $1,215 from $1,260 at RBC Capital
- Regeneron selloff ‘overdone’ with pipeline catalysts coming, says Morgan Stanley
- Regeneron price target lowered to $800 from $820 at BofA
- Regeneron earnings selloff ‘serious overreaction,’ says Piper Sandler